Companies: 10,795·Total market cap: $144.5T
BioNTech SE

BioNTech SE

BNTXNASDAQHealthcare● Active
$86.76
$-1.33(-1.50%)
Market Cap$21.9B
P/E Ratio—
52W High$124
52W Low$79.52
Overview

BioNTech SE (BNTX) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

BNTX · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$14.83B▼ -11.6% vs prior year
FY · as of Dec 31, 2025 · Reported in EUR
Cash & Cash Equiv. (CCE)
$7.67B
cashAndCashEquivalents
Short-Term Investments
$7.16B
shortTermInvestments
YoY Change vs Prior Year
-11.6%
vs prior fiscal year
Latest Quarter
$14.65B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in EUR

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$14.83BCash on Hand
Total Debt$267.3MTotal Debt
Net Cash / Net Debt+$14.57BNet Cash Position
Cash vs Debt Ratio
Cash 98%Debt 2%

BioNTech SE has a net cash position of $14.57B, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$14.83B − $267.3M = +$14.57B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
BNTX annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$14.83B-11.6%
Dec 31, 2024$16.78B+1.4%
Dec 31, 2023$16.55B+17.7%
Dec 31, 2022$14.06B+578.0%
Dec 31, 2021$2.07B+53.9%
BNTX cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.7%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%
#3
BioNTech SE
BioNTech SEYOU
BNTX
$14.83B67.6%
#4
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

BioNTech SE (BNTX) cash on hand as of December 31, 2025 is $14.83B, comprising $7.67B in cash and cash equivalents (CCE) plus $7.16B in short-term investments — reported as BioNTech SE cash and short-term investments on the balance sheet (10-K filing). Also referred to as BioNTech SE cash reserves or cash position.

BioNTech SE annual cash on hand history shows decreased -11.6% in 2025: decreased -11.6% in 2025. BioNTech SE cash reserves in 2025 reflect the company's capital allocation strategy.

BioNTech SE carries total debt of $267.3M against cash of $14.83B, resulting in a net cash position of +$14.57B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

BNTX cash on hand · 5 questions

As of December 31, 2025, BioNTech SE (BNTX) has $14.83B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $7.67B in cash and cash equivalents (CCE) plus $7.16B in short-term investments. Latest quarter (March 31, 2026): $14.65B. Data sourced from the annual 10-K filing via FMP.

BNTX cash on handBNTX cash reservesBNTX cash 2025how much cash does BNTX have

▸ Source: FMP /balance-sheet-statement · US GAAP · BioNTech SE · BioNTech SE SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025